FGF-18 truncated variants having increased receptor specificity and uses thereof
US9226949B2 · kind B2 · utility
2Cited by
3References
20Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 21, 2013 |
| Grant date | Jan 5, 2016 |
| Priority date | — |
| Expiry date | Mar 21, 2033 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K14/50
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to fibroblast growth factor 18 (FGF-18) variants having various truncations beyond the signal peptide domain of the N-terminus, which activate FGFR3 with increased specificity. The invention further relates to polynucleotides encoding the variants, pharmaceutical compositions comprising same and methods for use thereof in treating cartilage and skeletal disorders.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.